Filters

Jaleh Fallah, Sundeep Agrawal, Haley Gittleman, Mallorie H Fiero, Sriram Subramaniam, Christy John, Wei Chen, Tiffany K Ricks, Gang Niu, Anthony Fotenos, Min Wang, Kelly Chiang, William F Pierce, Daniel L Suzman, Shenghui Tang, Richard Pazdur, Laleh Amiri-Kordestani, Amna Ibrahim, Paul G Kluetz

Clinical cancer research : an official journal of the American Association for Cancer Research 2023;29(9):1651-1657

Free Full Text

Abstract

Yttrium-labelled peptides for therapy of NET.

Lisa Bodei, Marta Cremonesi, Chiara M Grana, Marco Chinol, Silvia M Baio, Stefano Severi, Giovanni Paganelli

European journal of nuclear medicine and molecular imaging 2012;39 Suppl 1():S93-102

Full Text

Abstract

High-Specific-Activity-I-MIBG versus Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma.

Abhishek Jha, David Taïeb, Jorge A Carrasquillo, Daniel A Pryma, Mayank Patel, Corina Millo, Wouter W de Herder, Jaydira Del Rivero, Joakim Crona, Barry L Shulkin, Irene Virgolini, Alice P Chen, Bhagwant R Mittal, Sandip Basu, Joseph S Dillon, Thomas A Hope, Carina Mari Aparici, Andrei H Iagaru, Rodney J Hicks, Anca M Avram, Jonathan R Strosberg, Ali Cahid Civelek, Frank I Lin, Neeta Pandit-Taskar, Karel Pacak

Clinical cancer research : an official journal of the American Association for Cancer Research 2022;27(11):2989-2995

Free Full Text

Abstract

Assessment of cell death mechanisms triggered by Lu-anti-CD20 in lymphoma cells.

E Azorín-Vega, E Rojas-Calderón, B Martínez-Ventura, J Ramos-Bernal, L Serrano-Espinoza, N Jiménez-Mancilla, D Ordaz-Rosado, G Ferro-Flores

Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 2018;138():73-77

Full Text

Abstract

A Randomized clinical trial evaluating the impact on survival and quality of life of Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217).

Jorge Hernando, Emmanuel Deshayes, Urbano Anido, Maddalena Sansovini, Catherine Ansquer, Angelina Filice, Sara Cingarlini, David Taïeb, Rocio Garcia-Carbonero, José Carlos Ruffinelli, Francesco Panzuto, Eric Baudin, Paula Jimenez-Fonseca, Jaume Capdevila, Magalie Haissaguerre, Thomas Walter, Sergio Baldari, Come Lepage, Guillermo Villacampa, Nicola Fazio, Javier Molina-Cerrillo, Teresa Alonso-Gordoa, Timon Vandamme, Maribel Del Olmo-García, Alice Durand, Virginia Pubul, Maria San-Roman-Gil, Belen Llana, Marta Benavent Viñuales, Amandine Beron, Rosa Álvarez-Álvarez, Laurence Lousberg, Frank Aboubakar Nana, Alejando García-Álvarez, Amparo García-Burillo

BMC cancer 2025;25(1):613

Free Full Text

Abstract

Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea.

Yeokyeong Shin, Bo Hyun Moon, Baek-Yeol Ryoo, Heung-Moon Chang, Kyu-Pyo Kim, Yong Sang Hong, Tae Won Kim, Jin-Sook Ryu, Yong-Il Kim, Changhoon Yoo

Targeted oncology 2024;19(1):41-49

Full Text

Abstract

Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?

Jolanta Kunikowska, Leszek Królicki, Alicja Hubalewska-Dydejczyk, Renata Mikołajczak, Anna Sowa-Staszczak, Dariusz Pawlak

European journal of nuclear medicine and molecular imaging 2012;38(10):1788-97

Free Full Text

Abstract

DNA Damage in Peripheral Blood Lymphocytes of Thyroid Cancer Patients After Radioiodine Therapy.

Uta Eberlein, Harry Scherthan, Christina Bluemel, Michel Peper, Constantin Lapa, Andreas Konrad Buck, Matthias Port, Michael Lassmann

Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2016;57(2):173-9

Free Full Text

Abstract

Results: 1 – 15 / 26

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Lutetium""[mesh_terms]

Comparative studies on the potential use of Lu-based radiopharmaceuticals for the palliative therapy of bone metastases.

Lutetium-177 DOTATATE: A Practical Review.

Alpha and Beta Radiation for Theragnostics.

Computational and experimental studies of the electronic excitation spectra of EDTA and DTPA substituted tetraphenylporphyrins and their Lu complexes.

Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective.

Dosimetry of Bone Seeking Beta Emitters for Bone Pain Palliation Metastases.

Tailored Reaction Conditions and Automated Radiolabeling of [177Lu]Lu-PSMA-ALB-56 in a 68Ga Setting: The Critical Impact of Antioxidant Concentrations.

FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer.

Yttrium-labelled peptides for therapy of NET.

High-Specific-Activity-I-MIBG versus Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma.

Assessment of cell death mechanisms triggered by Lu-anti-CD20 in lymphoma cells.

A Randomized clinical trial evaluating the impact on survival and quality of life of Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217).

Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea.

Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?

DNA Damage in Peripheral Blood Lymphocytes of Thyroid Cancer Patients After Radioiodine Therapy.

Results for
""Lutetium""[mesh_terms]

Tailored Reaction Conditions and Automated Radiolabeling of [¹⁷⁷Lu]Lu-PSMA-ALB-56 in a ⁶⁸Ga Setting: The Critical Impact of Antioxidant Concentrations.